What is Complement 1?
Complement 1 operates at the intersection of oncology and digital health, providing a sophisticated platform designed to support cancer patients, survivors, and high-risk individuals. By leveraging AI-driven insights, the company delivers personalized daily coaching that encompasses nutrition, physical activity, and mind-body interventions. This evidence-based approach has been clinically validated to reduce treatment side effects and improve overall patient quality of life. As a private health technology entity founded in 2024, Complement 1 is positioning itself as a critical player in the supportive care ecosystem, bridging the gap between traditional clinical treatment and holistic patient management.
The company's business model relies on the efficacy of its CoActive coaching framework, which is designed to be both scalable and highly personalized. By focusing on measurable patient outcomes, Complement 1 differentiates itself from generic wellness applications, targeting a high-acuity market segment that requires rigorous clinical oversight and data-backed interventions.
How much funding has Complement 1 raised?
Complement 1 has raised a total of $16M across 1 funding round:
Seed
$16M
Seed (2025): $16M with participation from Blume Ventures and Owl Ventures
Key Investors in Complement 1
Blume Ventures
Blume Ventures is an India focused early stage investment firm that backs founders from seed through scale up. With local insight and hands on support, it partners with teams building enduring technology led businesses across consumer, enterprise and deep tech, helping them raise capital, sharpen strategy and grow responsibly.
Owl Ventures
Owl Ventures is a global leader in education technology investing, focusing on innovative solutions that enhance learning experiences. The company supports a diverse range of edtech companies, including those providing tools for personalized tutoring, virtual classrooms, and workforce upskilling.
What's next for Complement 1?
With this major enterprise-level funding, Complement 1 is well-positioned to accelerate its market penetration and expand its clinical trial footprint. The strategic capital will likely be deployed toward enhancing its AI algorithms, scaling its network of certified coaches, and forging partnerships with major healthcare providers and oncology centers. As the company moves beyond its initial development phase, the focus will shift toward operational efficiency and proving the long-term economic value of its platform to payers and health systems. The backing from prominent venture firms suggests a clear path toward institutionalizing its lifestyle modification programs as a standard of care in oncology treatment protocols.
See full Complement 1 company page
